Arbutus Biopharma Corp financial data

Symbol
ABUS on Nasdaq
Location
701 Veterans Circle, Warminster, PA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 983 % +50.9%
Debt-to-equity 33.5 % +3.78%
Return On Equity -50.2 % +26.4%
Return On Assets -37.6 % +27%
Operating Margin -320 % +74%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 192M shares +1.5%
Common Stock, Shares, Outstanding 192M shares +1.33%
Entity Public Float 454M USD +57.7%
Common Stock, Value, Issued 1.42B USD +0.78%
Weighted Average Number of Shares Outstanding, Basic 192M shares +1.47%
Weighted Average Number of Shares Outstanding, Diluted 192M shares +1.47%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 14.6M USD +117%
Research and Development Expense 29M USD -53.7%
General and Administrative Expense 16.9M USD -24.8%
Operating Income (Loss) -46.8M USD +43.7%
Nonoperating Income (Expense) 4.53M USD -29.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -20.1M USD -14.4%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -42.3M USD +44.9%
Earnings Per Share, Basic 0 USD/shares +46.5%
Earnings Per Share, Diluted 0 USD/shares +46.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22.4M USD -29.6%
Cash, Cash Equivalents, and Short-term Investments 123M USD -7.33%
Accounts Receivable, after Allowance for Credit Loss, Current 905K USD -43.7%
Assets, Current 97.4M USD -26.6%
Property, Plant and Equipment, Net 137K USD -96.1%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 131K USD
Assets 97.7M USD -30.4%
Liabilities, Current 5.18M USD -72.6%
Operating Lease, Liability, Noncurrent 391K USD -60%
Liabilities 20.3M USD -39.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -48.1M USD -0.08%
Retained Earnings (Accumulated Deficit) -1.38B USD -3.17%
Stockholders' Equity Attributable to Parent 77.4M USD -27.6%
Liabilities and Equity 97.7M USD -30.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13.4M USD +30.6%
Net Cash Provided by (Used in) Financing Activities 2.78M USD -88.6%
Net Cash Provided by (Used in) Investing Activities 11.3M USD -2.95%
Common Stock, Shares, Issued 192M shares +1.33%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 746K USD -95.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 22.4M USD -29.6%
Deferred Tax Assets, Valuation Allowance 175M USD +7.16%
Operating Lease, Liability 1.29M USD -27.1%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -42.3M USD +44.3%
Lessee, Operating Lease, Liability, to be Paid 1.42M USD -30.3%
Property, Plant and Equipment, Gross 16.3M USD -1.62%
Operating Lease, Liability, Current 531K USD +13.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 654K USD +2.99%
Lessee, Operating Lease, Liability, to be Paid, Year One 634K USD +2.92%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 133K USD -50.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 134K USD -79.5%
Deferred Tax Assets, Operating Loss Carryforwards 96.1M USD +7.84%
Preferred Stock, Shares Authorized 1.16M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Additional Paid in Capital 83.3M USD +2.28%
Depreciation, Depletion and Amortization 330K USD -7.04%
Share-based Payment Arrangement, Expense 4.89M USD -46.1%
Interest Expense 168K USD -84.8%